Psoriasis injection okayed for limited use to treat Covid-19 patients: Drug controller

The approval was given after its clinical trials on Covid-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome
Written informed consent of each patient is required before the use of this drug.(AP)
Written informed consent of each patient is required before the use of this drug.(AP)
Updated on Jul 11, 2020 10:40 PM IST
Copy Link
New Delhi, Delhi | ByPress Trust of India | Posted by Shivani Kumar

India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for “restricted emergency use” to treat Covid-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.

Considering the unmet medical needs to treat Covid-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to Covid-19, they said.

“The approval was given after its clinical trials on Covid-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome,” an official told PTI.

“It is already an approved drug of Biocon for treating psoriasis for last many years,” the official said.

Written informed consent of each patient is required before the use of this drug, he said.

SHARE THIS ARTICLE ON
Close Story
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Wednesday, January 26, 2022